NICE states that the Cochrane review provides no new evidence

Announcement Date: October 1, 2014
Final recommendation post consultation: The technology appraisal programme recommends that, as proposed to consultees, TA158 should remain on the ‘static guidance list’ and TA168 is transferred to the ‘static guidance list’

National Institute of Clinical Excellence. Review of TA158; Oseltamivir, amantadine and zanamivir for the prophylaxis of influenza, and TA168; Amantadine, oseltamivir and zanamivir for the treatment of influenza)

The paper stated: We consider that the results of the Cochrane update are unlikely to change the recommendations of TA158 and TA168.

Explore the CEBM